The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics.
S V
SV
Vormfelde
M R
MR
Toliat
M
M
Schirmer
I
I
Meineke
P
P
Nürnberg
J
J
Brockmöller
D000409:Alanine / Q000235:genetics; D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001216:Asparagine / Q000235:genetics; D001224:Aspartic Acid / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D013449:Sulfonamides / Q000493:pharmacokinetics*; D000077786:Torsemide; D014633:Valine / Q000235:genetics
D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D013449:Sulfonamides; D001224:Aspartic Acid; D001216:Asparagine; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D014633:Valine; D000409:Alanine; D000077786:Torsemide